Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
Disease control
Completed
This phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…
Phase: PHASE2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC